The EU bet pretty heavily on AstraZeneca and that's not the Eastern European countries fault. The EU already ordered in August, while they only ordered from Biontech and Moderna in November (11th and 25th). It wasn't wrong to buy AstraZeneca, it's cheap and more importantly easy to handle. The failure was to bet so much on it. AstraZeneca wasn't something that was odered as well, it was and still is THE vaccine that's intended for the largest part of the population.
Money also can't be an issue, the EU has come up with 750B euros to fight the economical impact of the pandemics. That was already in April or so. For the vaccine the EU only had around 2.7B available for most of 2020. The UK alone spent more than that, the US over 10B$. The worst thing: 2B of those 2.7B euros were simply repurposed from an already existing fund. That means the EU states only had to come up with 700M euros together in total. Even ignoring all of that, the vaccine is so cheap compared to the costs of lockdowns (and lives) that the price simply does not matter much. Ironically the price they got is the part the EU is especially proud of and EU politicans are quick to point out that Israel payed twice as much per dose.
What they don't say that the Pfizer/Biontech vaccine's price depends on the amount and delivery date. So you could actually pay more to get the vaccine sooner. It seems the EU chose not to do that because they felt good enough with AstraZeneca (they were supposed to start production in October). Unfortunately that information isn't public so we don't know for sure. But this would both explain why the EU didn't expect significant shipments from Non-AZ vaccines in the first quarter and why they got it cheaper.
Money also can't be an issue, the EU has come up with 750B euros to fight the economical impact of the pandemics. That was already in April or so. For the vaccine the EU only had around 2.7B available for most of 2020. The UK alone spent more than that, the US over 10B$. The worst thing: 2B of those 2.7B euros were simply repurposed from an already existing fund. That means the EU states only had to come up with 700M euros together in total. Even ignoring all of that, the vaccine is so cheap compared to the costs of lockdowns (and lives) that the price simply does not matter much. Ironically the price they got is the part the EU is especially proud of and EU politicans are quick to point out that Israel payed twice as much per dose.
What they don't say that the Pfizer/Biontech vaccine's price depends on the amount and delivery date. So you could actually pay more to get the vaccine sooner. It seems the EU chose not to do that because they felt good enough with AstraZeneca (they were supposed to start production in October). Unfortunately that information isn't public so we don't know for sure. But this would both explain why the EU didn't expect significant shipments from Non-AZ vaccines in the first quarter and why they got it cheaper.